La vendita allo scoperto per Hodogaya Chemical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Hodogaya Chemical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Hodogaya Chemical (OTC:HCHCF) Azioni, Report sulle vendite allo scoperto

Hodogaya Chemical Co Ltd manufactures and sells functional colorants, specialty polymers, basic chemicals, and agro-science products in Japan. The firm's product includes imaging materials, dyes, colors, food additives, and organic light emitting diode materials. The Functional Polymers unit consists of urethane and cement-based construction and civil engineering materials, polyol, and basic raw materials for general chemistry industry. Basic Chemicals handles production of hydrogen peroxide. Agro-Science unit deals with herbicides, pesticides, and growth control agents for crop fields, golf courses, and green areas. Logistic services include warehousing, cargo transport, and commissioned research businesses.

HODOGAYA CHEMICAL CO by HODOGAYA CHEMICAL CO LTD.

Hodogaya Chemical Co Ltd

Trading Ideas

BAOS

Baosheng Media Group Shares Resume Trading

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $8 price target.

News

Price Target

Reiteration

Analyst Ratings

IBRX

HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $8 Price Target

Baosheng Media Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 112.9%

Needham analyst Serge Belanger reiterates Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) with a Buy and maintains $25 price target.

LQDA

Needham Reiterates Buy on Liquidia, Maintains $25 Price Target

AVGO

Live On CNBC, Stephanie Link Announces Bought More Broadcom

Baosheng Media Group Shares Resume Trade

WBUY

Webuy Global Shares Resume Trade

Needham analyst Ryan MacDonald reiterates Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) from Hold to Hold.

CHGG

Needham Reiterates Hold on Cheggto Hold

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and maintains $4 price target.

ATNM

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target

Baosheng Media Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 68.8%

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 900 points on Monday.
The Dow traded up 2.20% to 42,155.11 while the NASDAQ gained 3.59% to 18,572.58. The S&amp;P 500 also rose, gaining, 2.59% to 5,806.23.
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 4.8% on Monday.
In trading on Monday, consumer staples stocks fell by 0.4%.
Top Headline
NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) reported better-than-expected first-quarter financial results.
NRG Energy posted adjusted earnings of $2.62 per share, beating market estimates of $1.49 per share. The company's quarterly sales came in at $8.59 billion versus expectations of $7.83 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Gryphon Digital Mining, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares shot up 274% to $1.9450 after the company announced a merger agreement with American Bitcoin.</li>
<li>Shares of Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) got a boost, surging 407% to $19.77 after the company announced a merger agreement with Nakamoto Holdings to start a Bitcoin treasury strategy.</li>
<li>NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) shares were also up, gaining 22% to $145.08 after the company reported better-than-expected first-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Superior Industries International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) shares dropped 69% to $0.8950 after the company reported worse-than-expected first-quarter EPS results and announced it is withdrawing its FY25 guidance.</li>
<li>Shares of Orla Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#NYSE">ORLA</a>) were down 16% to $9.27 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Pan American Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) was down, falling 14% to $23.30 after the company announced it entered into an agreement to acquire all of the issued and outstanding common shares of MAG Silver.</li>
</ul>
Commodities In commodity news, oil traded up 3.2% to $62.96 while gold traded down 2.9% at $3,247.10.
Silver traded down 0.2% to $32.84 on Monday, while copper fell 0.8% to $4.6175.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.89%, while Spain's IBEX 35 Index rose 0.28%. London's FTSE 100 gained 0.35%, Germany's DAX 40 gained 0.02% and France's CAC 40 gained 1.18% during the session.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei gaining 0.38%, Hong Kong's Hang Seng Index gaining 2.98%, China's Shanghai Composite Index gaining 0.82% and India's BSE Sensex jumping 3.74%.
Economics
The U.S. government budget report for April will be released today.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45347296/this-target-analyst-turns-bearish-here-are-top-5-downgrades-for-monday">This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

GRYP

KDLY

ORLA

PAAS

Dow Jumps 900 Points; KindlyMD Shares Spike Higher

Webuy Global Shares Halted On Circuit Breaker To The Downside, Stock Now Down -31.4%

RBC Capital analyst Daniel Perlin maintains TaskUs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) with a Sector Perform and lowers the price target from $20 to $16.5.

TASK

RBC Capital Maintains Sector Perform on TaskUs, Lowers Price Target to $16.5

RBC Capital analyst Matthew McKellar maintains Sylvamo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLVM#NYSE">SLVM</a>) with a Sector Perform and lowers the price target from $70 to $61.

SLVM

RBC Capital Maintains Sector Perform on Sylvamo, Lowers Price Target to $61

Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Spectral AI will report an earnings per share (EPS) of $-0.15.
The market awaits Spectral AI's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.27 in the last quarter, leading to a 11.72% drop in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2025/1747066029_0.png" alt="eps graph" />
<h3>Tracking Spectral AI's Stock Performance</h3>
Shares of Spectral AI were trading at $1.24 as of May 09. Over the last 52-week period, shares are down 22.78%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/MDAI/earnings">To track all earnings releases for Spectral AI visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MDAI

What's Next: Spectral AI's Earnings Preview

RBC Capital analyst Darko Mihelic maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Outperform and raises the price target from C$82 to C$88.

TSX:SLF

RBC Capital Maintains Outperform on Sun Life Financial, Raises Price Target to C$88

Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Lineage Cell Therapeutics to report an earnings per share (EPS) of $-0.03.
Anticipation surrounds Lineage Cell Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 0.36% increase in the share price the following trading session.
Here's a look at Lineage Cell Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.03</td>
<td>-0.03</td>
<td>-0.04</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.03</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747065929_0_0.png" alt="eps graph" />
<h3>Tracking Lineage Cell Therapeutics's Stock Performance</h3>
Shares of Lineage Cell Therapeutics were trading at $0.44 as of May 09. Over the last 52-week period, shares are down 55.36%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Opinions on Lineage Cell Therapeutics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Lineage Cell Therapeutics.
Analysts have provided Lineage Cell Therapeutics with 5 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $5.0, suggesting a potential 1036.36% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of and Macrogenics, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Macrogenics, with an average 1-year price target of $2.0, suggesting a potential 354.55% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary provides a snapshot of key metrics for and Macrogenics, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lineage Cell Therapeutics</td>
<td>Buy</td>
<td>37.36%</td>
<td>$2.71M</td>
<td>-4.53%</td>
</tr>
<tr>
<td>Macrogenics</td>
<td>Neutral</td>
<td>93.47%</td>
<td>$12.24M</td>
<td>-13.06%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Lineage Cell Therapeutics ranks higher than its peers in Revenue Growth and Gross Profit, indicating strong performance in these areas. However, it lags behind in Return on Equity. Overall, Lineage Cell Therapeutics is positioned in the middle compared to its peers based on the provided metrics.
<h3>Discovering Lineage Cell Therapeutics: A Closer Look</h3>
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
<h3>Financial Insights: Lineage Cell Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Lineage Cell Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 37.36%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Lineage Cell Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -114.12%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Lineage Cell Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lineage Cell Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.12% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Lineage Cell Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/LCTX/earnings">To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LCTX

Examining the Future: Lineage Cell Therapeutics's Earnings Outlook

WIIM

RMTI

RMTI stock has given up its prior gain. Rockwell Medical shares were trading higher after the company reported better-than-expected Q1 financial results.

RBC Capital analyst Darko Mihelic maintains Sun Life Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLF#NYSE">SLF</a>) with a Outperform and raises the price target from $82 to $88.

RBC Capital Maintains Outperform on Sun Life Financial, Raises Price Target to $88

The Consumer Price Index for April, due Tuesday morning, could test Wall Street's renewed bullishness after a major U.S.-China tariff rollback<a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation"> fueled risk-on sentiment. </a>
Despite a slightly defused trade war, the inflation print could tighten the Fed's hand further, especially if prices came in hotter than forecast.
Wall Street economists agree that the annual headline inflation rate will remain at 2.4%—the 49th straight month above the Federal Reserve's 2% target.
Inflation is forecast to rebound from a 0.1% drop in March to 0.3% in April. Core CPI, which excludes food and energy, is expected to rise 0.3% monthly and hold steady at 2.8% annually.
Bank America&#8217;s economist Stephen Juneau warns that "larger increases are in the pipeline" due to front-loaded demand and the lingering impact of April's tariff shock.
See Also: <a href="https://www.benzinga.com/news/earnings/earnings-misses/25/05/45353447/amc-networks-sales-drop-as-analyst-warns-of-continued-pressure-on-revenue">AMC Networks&#8217; Sales Drop As Analyst Warns Of &#8216;Continued Pressure&#8217; On Revenue</a>
<h3 class="wp-block-heading">Fed Rate Cut Expectations Collapse After US-China Trade Truce</h3>
The surprise U.S.-China trade breakthrough on Monday delivered another blow to short-term Fed cut bets. With tariffs slashed by over 100 percentage points for at least 90 days, economic uncertainty tied to supply chains and pricing has decreased. 
Markets now price just an 8% probability of a 25-basis-point cut in June, according to CME FedWatch data. That's down from nearly 40% a week ago. The odds for a July cut stand at 42%, while expectations for two cuts by December have dropped to 72%, from nearly three cuts priced before last week's FOMC meeting.
The Federal Reserve kept rates unchanged for a third consecutive meeting in May and emphasized that "uncertainty about the economic outlook has increased," citing risks of both higher unemployment and persistent inflation. 
Fed Chair Jerome Powell said policy is in a "good place" and the central bank will wait for more clarity on trade and prices.
 "Inflation remains above the Federal Open Market Committee's 2% target, and further progress on disinflation has been slow," said Fed Governor Adriana Kugler on Monday, reinforcing the central bank's cautious stance.
<h3 class="wp-block-heading">Tariffs: A Short-Term Boost To Prices?</h3>
While the U.S.-China truce reduces long-term inflation risk, at least from a supply-side perspective, April may still show upward price pressures as businesses and consumers reacted to the previous tariff escalation. 
Bank of America indicates that tariff revenues and effective rates rose about 2 percentage points in April — a modest but broad-based input cost pressure.
Core goods inflation is expected to rise 0.1% month-over-month after a 0.1% drop in March, driven by front-loaded demand and rising auto prices. Juneau highlighted a 2.7% monthly spike in the Manheim Used Vehicle Value Index as another red flag.
"Tariffs should be a modest boost to goods prices this month," Juneau said, "but larger increases are in the pipeline."
Services inflation may be tamer. The analyst expects a slight moderation in rent inflation and is watching categories like airfares, lodging and car rentals for signs of weakening demand, which is already visible in card spending data.
According to veteran Wall Street investor Ed Yardeni, &#8220;increases like the 2.7% month-over-month jump in the Manheim Used Vehicle Value Index in April from March bear watching.&#8221;
&#8220;Higher prices paid for imports due to tariffs are also driving up service sector firms' costs, feeding through to higher prices, notably in consumer-facing industries such as restaurants and hotels,&#8221; said S&amp;P Global&#8217;s chief economist Chris Williamson in the latest U.S. Services PMI report.
<h3 class="wp-block-heading">What To Expect In Markets</h3>
It's unlikely Tuesday's inflation report derails Wall Street&#8217;s tariff-relief rally—unless the numbers come in well above expectations. 
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — which tracks the S&amp;P 500 index — surged 2.6% on Monday to an over two-month high on hopes that the trade truce reduces supply-side price pressures and stabilizes global growth.
Still, sticky inflation would signal that the Fed's 2% goal remains distant, reinforcing its higher-for-longer interest rate stance. A hotter April inflation print might strengthen the dollar and increase bond yields.
The U.S. dollar, which weakened during April's tariff escalation, is <a href="https://www.bloomberg.com/quote/BBDXY:IND?sref=TBDibEcD">rebounding</a> as of May 12. Meanwhile, Treasury yields are climbing: the 30-year bond yield hovered at 4.87% on Monday, near its 2025 high of 5%.
Now Read: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45339399/trump-says-prescription-drug-prices-set-to-drop-by-30-to-80-almost-immediately-thanks-to-most-favored-nation-plan-mark-cuban-urges-president-to-force-tran">Trump Says Prescription Drug Prices Set To Drop By 30% To 80% &#8216;Almost Immediately,&#8217; Mark Cuban Urges President To &#8216;Force Transparency&#8217;</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Image: Shutterstock

Comments

Hodogaya Chemical

Vendite allo scoperto

Hodogaya Chemical (OTC:HCHCF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO